Peptide Therapy: Overview and Safety — What's a Drug, and What's a Gray Market

"Peptide therapy" is today one of the most-searched terms in biohacking — from anti-aging clinics to gym forums. The problem is that the same label covers two completely different worlds. On one side there's a handful of peptides that went through full, multi-year drug registration — clinical trials, manufacturing quality control, and a specific, approved indication. On the other side there are dozens, if not hundreds, of other compounds sold by online vendors as "research use only," with no oversight whatsoever of purity, sterility, or what's actually in the vial.

That distinction isn't a semantic nitpick. A drug approved by the FDA or the EMA (the European Medicines Agency) has gone through a process in which the manufacturer must demonstrate repeatable purity, stability, and safety at specific doses in a specific patient population. A substance sold as a "research chemical" goes through none of that before reaching the customer — full responsibility for what's actually in the vial rests with an unregulated supplier.

Peptides are short chains of amino acids — smaller and simpler than full proteins, but working on a similar principle: they bind to specific cell receptors and trigger a specific biological response. That specificity is exactly what makes them pharmacologically attractive — in theory you can design a peptide that hits precisely the mechanism you want, with fewer side effects than a broader-acting drug.

In practice, designing such a compound is only the first step. What follows is years of preclinical animal research, then three phases of human clinical trials checking safety, efficacy, and optimal dosing, and finally a registration process with a drug agency. The vast majority of peptides you read about online in a biohacking context never got further than early animal studies — and that's the key gap that "research chemical" marketing consistently glosses over.

The list of peptides with full drug registration is short, but real. Semaglutide and tirzepatide (sold under brand names like Ozempic, Wegovy, Mounjaro, and Zepbound) are FDA-approved drugs for type 2 diabetes and obesity — in December 2024, tirzepatide additionally received US approval for treating moderate to severe obstructive sleep apnea in adults with obesity, based on two clinical trials covering 469 participants followed for 52 weeks. Tesamorelin (Egrifta) is a growth-hormone-releasing peptide, FDA-approved back in 2010 for excess visceral fat in HIV patients with lipodystrophy — the first approved drug for that indication, with a newer formulation approved in 2025.

It's worth stressing: a peptide being approved doesn't automatically mean it's risk-free, or that every off-label use is safe. It only means that, in the specific, studied application and dosage, an independent regulatory body judged the benefits to outweigh the documented risk — a fundamentally different situation from having no data at all.

Beyond that narrow group of approved drugs there's a much larger market of peptides such as BPC-157, TB-500, ipamorelin, CJC-1295, and GHK-Cu, which we cover in more depth in a dedicated article about BPC-157 — a representative example of this whole category. These are sold almost exclusively by online vendors under labels like "not for human consumption" or "research use only," which is in practice a legal loophole for dodging drug regulations, not confirmation of any quality or safety control.

The most serious, documented problem with unapproved peptides isn't the lack of efficacy evidence itself — that's at worst wasted money. More serious is what actually ends up in the vial. Independent lab analyses of gray-market products have repeatedly found contamination with bacterial endotoxins (fragments of bacterial cell walls), which can trigger fever, systemic inflammation, and in extreme cases septic-shock-like reactions — plus mismatches between the vial's actual contents and what's on the label.

On top of that there's a structural problem: with no standardized dose, users "titrate" dosing themselves based on internet forums, with no way to verify whether the vial actually contains the declared concentration. In 2024 and 2025 the FDA issued more than 50 warning letters to vendors and compounding pharmacies over illegal peptide sales, and an international Interpol operation targeting illegal pharmaceutical substances (peptides included) led to nearly 770 arrests and the seizure of goods worth more than $65 million worldwide over the same period.

The FDA also oversees so-called compounding pharmacies, which under certain conditions may legally prepare formulations from substances not registered as a finished drug — but only from an approved bulk substances list, and only by prescription. Several popular "research peptides," including BPC-157, were in recent years formally determined by the FDA not to qualify for that list, which in practice restricts the legal path to obtaining them even through compounding pharmacies — yet they remain widely available in direct-to-consumer online sales.

The World Anti-Doping Agency (WADA) has for years placed a broad category of peptide hormones, growth factors, and related substances (category S2 of the prohibited list) on its year-round ban in competitive sport, both in and out of competition. This covers both growth-hormone-releasing peptides (like GHRP-2, GHRP-6, ipamorelin, or CJC-1295) and other substances in this class, regardless of whether a given specific compound has formal drug approval or not.

That's an additional, practical argument for caution among both amateur and competitive athletes: the mere fact that a peptide is easily available online doesn't mean using it is legal in a sporting context — and detecting metabolites of these substances in an anti-doping test carries sanctions regardless of where the product came from.

Peptides as a molecular class are neither a miracle solution nor inherently dangerous — it's a broad, varied category in which a few compounds went through the full, rigorous registration process and today treat real health problems under medical supervision. The problem starts where marketing blurs the line between that narrow group and hundreds of other substances sold with identical confidence, but without any of the accompanying evidence, quality control, or oversight.

If a given peptide actually has a documented clinical use, the right path is a prescription and a doctor's supervision, not an order from an online store labeled "not for human consumption." For peptides without full approval, the reasonable approach is to wait for evidence from human trials rather than being part of an uncontrolled self-experiment whose results no one is systematically collecting.